CSL Limited
- Updated
- World markets
ASX bounces to 50-day high as CBA, AGL soar
Shares in Commonwealth Bank bounced after it revealed a $5.4 billion half-year profit leading the ASX higher.
- Staff reporter
Latest
How RFK, China and leadership woes became a $4b storm for this Australian corporate giant
CSL’s share price has now halved in 18 months, shredding more than $70 billion of shareholder wealth after the latest writedowns and operational struggles.
- Colin Kruger
- Opinion
- Earnings season
The good, the bad and the very ugly of profit season
It’s still early in the earnings season, but already we have two chief executive beheadings, while one of the big four banks has posted a stellar result.
- Elizabeth Knight
Boss of $83b giant CSL exits abruptly
Australian pharmaceuticals heavyweight CSL says its chief executive Paul McKenzie is leaving the company with immediate effect.
- Clancy Yeates
This gene therapy costs $5 million a dose. Is it worth the price?
A new wave of gene therapy treatments offer a new lease on life for people with inherited diseases such as haemophilia. But there’s a $5 million problem.
- Liam Mannix
- Analysis
- Anti-vaxxer movement
How Trump’s antivaxxers helped trigger Aussie giant’s $50b implosion
The deadliest US flu season in decades was expected to immunise CSL’s vaccine business from a growing anti-vaxxer sentiment. That’s not how it has played out.
- Colin Kruger
- Updated
- Vaccination
Aussie giant takes $17b hit as more Americans shun vaccines
A further plunge in US vaccination rates since the appointment of vaccine sceptic Robert F. Kennedy Jr has sparked a fresh earnings blow to biotech giant CSL.
- Colin Kruger
- Exclusive
- Trade wars
Mission critical: Australia keen to lock in new US deal before Trump meeting
Canberra is negotiating with the president’s lieutenants to guarantee the Americans access to the elements needed to build everything from smartphones to fighter jets.
- Paul Sakkal and Nick Newling
Break ground by Wednesday or else: Trump imposes 100 per cent tariff on pharmaceuticals
Shares in domestic biotechnology giant CSL dropped 3.6 per cent after Trump announced the tariff on Truth Social.
- Nick Newling
- Updated
- World markets
ASX starts week in the red; miners weak, CBA slips
The Australian sharemarket pared early losses but has started the week lower as miners weigh on the bourse.
- Staff reporter